Deferasirox 500 MG Tablet for Oral Suspension — RxCUI 597772
RxNorm drug concept · Semantic clinical drug
RxCUI 597772
Semantic clinical drug · SCD
● Current RxNorm concept 35 FDA products
62 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI597772
Official nameDeferasirox 500 MG Tablet for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped35
Package NDCs mapped62
Reported Medicaid activity (SDUD)455 prescriptions · 9 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Deferasirox: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Deferasirox is an iron chelator — think of it like a molecular magnet that grabs onto excess iron in your body and carries it out, mostly through your stool. When you get lots of b...
- What exactly is deferasirox doing in my body?
- It depends on which product you have. Jadenu tablets can be taken with water or a light meal — that's fine. But a high-fat meal (think a full cheeseburger and fries) increases how...
- Nausea, vomiting, diarrhea, stomach pain, and a mild skin rash are common and often manageable — mild rashes sometimes go away on their own without changing the dose. But call your...
🕸️ Concept Web — How Deferasirox 500 MG Tablet for Oral Suspension Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Deferasirox 500 MG Tablet for Oral Suspension
RxCUI 597772 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Deferasirox
614373IN
-
Deferasirox
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Exjade
614084BN
-
Exjade
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Deferasirox Tablet for Oral Suspension
1869534SCDF -
Deferasirox Oral Liquid Product
1157196SCDG -
Deferasirox Oral Product
1157197SCDG -
Deferasirox Tablet for Oral Suspension [Exjade]
1869537SBDF -
Exjade Oral Liquid Product
1173264SBDG -
Exjade Oral Product
1173265SBDG -
Tablet for Oral Suspension
1861409DF -
Oral Liquid Product
1151137DFG - +1 more in this family
-
Deferasirox Tablet for Oral Suspension
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Deferasirox 500 MG
1869544SCDC -
Deferasirox 500 MG Tablet for Oral Suspension [Exjade]
616163SBD -
Deferasirox 500 MG [Exjade]
1869546SBDC
-
Deferasirox 500 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Deferasirox 500 MG
SCDC · 1869544 -
Deferasirox Tablet for Oral Suspension
SCDF · 1869534 -
Deferasirox Oral Liquid Product
SCDG · 1157196 -
Deferasirox Oral Product
SCDG · 1157197
Brand-Name Concepts
-
Deferasirox 500 MG Tablet for Oral Suspension [Exjade]
SBD · 616163 -
Deferasirox 500 MG [Exjade]
SBDC · 1869546 -
Deferasirox Tablet for Oral Suspension [Exjade]
SBDF · 1869537 -
Exjade Oral Liquid Product
SBDG · 1173264 -
Exjade Oral Product
SBDG · 1173265 -
Exjade
BN · 614084
📦 FDA Products & Package NDCs
35 products · 62 package NDCs
62 package NDCs map to RxCUI 597772 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00078-0468-15 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0468-15) | Exjade | Novartis Pharmaceuticals Corporation | 2005-11-30 |
| 00078-0469-15 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0469-15) | Exjade | Novartis Pharmaceuticals Corporation | 2005-11-30 |
| 00078-0470-15 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-0470-15) | Exjade | Novartis Pharmaceuticals Corporation | 2005-11-30 |
| 00480-7011-56 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0480-7011-56) | Deferasirox | Teva Pharmaceuticals, Inc. | 2024-11-01 |
| 00480-7012-56 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0480-7012-56) | Deferasirox | Teva Pharmaceuticals, Inc. | 2024-11-01 |
| 00480-7013-56 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (0480-7013-56) | Deferasirox | Teva Pharmaceuticals, Inc. | 2024-11-01 |
| 43598-0854-05 | 500 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-854-05) | Deferasirox | Dr. Reddy's Laboratories Inc | 2019-11-20 |
| 43598-0854-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-854-30) | Deferasirox | Dr. Reddy's Laboratories Inc | 2019-11-20 |
| 43598-0854-90 | 90 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-854-90) | Deferasirox | Dr. Reddy's Laboratories Inc | 2019-11-20 |
| 43598-0855-10 | 1000 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-855-10) | Deferasirox | Dr. Reddy's Laboratories Inc | 2019-11-20 |
| 43598-0855-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-855-30) | Deferasirox | Dr. Reddy's Laboratories Inc | 2019-11-20 |
| 43598-0855-90 | 90 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-855-90) | Deferasirox | Dr. Reddy's Laboratories Inc | 2019-11-20 |
| 43598-0856-10 | 1000 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-856-10) | Deferasirox | Dr. Reddy's Laboratories Inc | 2019-11-20 |
| 43598-0856-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-856-30) | Deferasirox | Dr. Reddy's Laboratories Inc | 2019-11-20 |
| 43598-0856-90 | 90 TABLET, FOR SUSPENSION in 1 BOTTLE (43598-856-90) | Deferasirox | Dr. Reddy's Laboratories Inc | 2019-11-20 |
| 45963-0455-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (45963-455-30) | Deferasirox | Actavis Pharma, Inc. | 2019-03-22 |
| 45963-0456-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (45963-456-30) | Deferasirox | Actavis Pharma, Inc. | 2019-03-22 |
| 46708-0324-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (46708-324-30) | Deferasirox | Alembic Pharmaceuticals Limited | 2019-11-21 |
| 46708-0325-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (46708-325-30) | Deferasirox | Alembic Pharmaceuticals Limited | 2019-11-21 |
| 46708-0326-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (46708-326-30) | Deferasirox | Alembic Pharmaceuticals Limited | 2019-11-21 |
| 62332-0324-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62332-324-30) | Deferasirox | Alembic Pharmaceuticals Inc. | 2019-11-21 |
| 62332-0325-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62332-325-30) | Deferasirox | Alembic Pharmaceuticals Inc. | 2019-11-21 |
| 62332-0326-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62332-326-30) | Deferasirox | Alembic Pharmaceuticals Inc. | 2019-11-21 |
| 62756-0568-83 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-568-83) | deferasirox | Sun Pharmaceutical Industries, Inc. | 2019-12-02 |
| 62756-0568-86 | 60 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-568-86) | deferasirox | Sun Pharmaceutical Industries, Inc. | 2019-12-02 |
| 62756-0569-83 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-569-83) | deferasirox | Sun Pharmaceutical Industries, Inc. | 2019-12-02 |
| 62756-0569-86 | 60 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-569-86) | deferasirox | Sun Pharmaceutical Industries, Inc. | 2019-12-02 |
| 62756-0570-83 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-570-83) | deferasirox | Sun Pharmaceutical Industries, Inc. | 2019-12-02 |
| 62756-0570-86 | 60 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-570-86) | deferasirox | Sun Pharmaceutical Industries, Inc. | 2019-12-02 |
| 67877-0549-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (67877-549-30) | Deferasirox | Ascend Laboratories, LLC | 2019-11-22 |
| 67877-0550-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (67877-550-30) | Deferasirox | Ascend Laboratories, LLC | 2019-11-22 |
| 67877-0551-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (67877-551-30) | Deferasirox | Ascend Laboratories, LLC | 2019-11-22 |
| 68462-0494-90 | 90 TABLET, FOR SUSPENSION in 1 BOTTLE (68462-494-90) | deferasirox | Glenmark Pharmaceuticals Inc., USA | 2020-01-06 |
| 68462-0495-90 | 90 TABLET, FOR SUSPENSION in 1 BOTTLE (68462-495-90) | deferasirox | Glenmark Pharmaceuticals Inc., USA | 2020-01-06 |
| 68462-0496-90 | 90 TABLET, FOR SUSPENSION in 1 BOTTLE (68462-496-90) | deferasirox | Glenmark Pharmaceuticals Inc., USA | 2020-01-06 |
| 69452-0159-13 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69452-159-13) | Deferasirox | Bionpharma Inc. | 2018-09-28 |
| 69452-0160-13 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69452-160-13) | Deferasirox | Bionpharma Inc. | 2018-09-28 |
| 69452-0161-13 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69452-161-13) | Deferasirox | Bionpharma Inc. | 2018-09-28 |
| 69539-0021-06 | 10 BLISTER PACK in 1 CARTON (69539-021-06) / 10 TABLET, FOR... | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2020-02-12 |
| 69539-0021-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-021-30) | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2019-11-20 |
| 69539-0021-90 | 90 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-021-90) | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2019-11-20 |
| 69539-0021-99 | 1000 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-021-99) | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2019-11-20 |
| 69539-0022-06 | 10 BLISTER PACK in 1 CARTON (69539-022-06) / 10 TABLET, FOR... | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2020-02-12 |
| 69539-0022-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-022-30) | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2019-11-20 |
| 69539-0022-90 | 90 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-022-90) | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2019-11-20 |
| 69539-0022-99 | 1000 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-022-99) | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2019-11-20 |
| 69539-0023-05 | 500 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-023-05) | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2019-11-20 |
| 69539-0023-06 | 10 BLISTER PACK in 1 CARTON (69539-023-06) / 10 TABLET, FOR... | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2020-02-12 |
| 69539-0023-30 | 30 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-023-30) | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2019-11-20 |
| 69539-0023-90 | 90 TABLET, FOR SUSPENSION in 1 BOTTLE (69539-023-90) | Deferasirox | MSN LABORATORIES PRIVATE LIMITED | 2019-11-20 |
Observed labelers:
MSN LABORATORIES PRIVATE LIMITED (12) ·
Novadoz Pharmaceuticals LLC (12) ·
Dr. Reddy's Laboratories Inc (9) ·
Sun Pharmaceutical Industries, Inc. (6) ·
Alembic Pharmaceuticals Inc. (3) ·
Alembic Pharmaceuticals Limited (3)
· +6 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.